Embecta Stock (NASDAQ:EMBC), Trade Ideas

Embecta

Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

Long Ideas

News

Small Cap

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

EMBC

Although US stocks closed higher on Wednesday, there were a few notable insider trades.

Insiders Buying V.F. Corporation And 2 Other Stocks

Earnings

Large Cap

Guidance

Health Care

General

Embecta Shares Gain As Q1 Earnings Exceed Expectations

Penny Stocks

Intraday Update

Movers

CIFR

FUSN

GNUS

MARA

MNDY

OPEN

OSCR

PLTR

RBOT

SKYT

U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Tuesday. Here are some big stocks recording gains in today’s session.

Avis Budget, Zoetis, Palantir Technologies And Other Big Stocks Moving Higher On Tuesday

Embecta Corp

Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintains Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) with a Market Perform and lowers the price target from $46 to $41.

Price Target

Analyst Ratings

CATY

Keefe, Bruyette & Woods Maintains Market Perform on Cathay General, Lowers Price Target to $41

PPSI

Pioneer Disclosed That It Received Nasdaq Notification Of Non-compliance Related To Delayed Annual Report On Form 10-K

Macro Economic Events

Econ #s

Economics

USA Redbook (YoY) 5.1% Vs 4.9% Prior

ECPG

Encore Capital Group Announced That It Has Established A Partnership With Junior Achievement USA To Empower Youth Through Financial Education

PIRS

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

ZAPP

BPTS

WIIM

RGEN

Repligen shares are trading higher as life sciences stocks gain following strong earnings from Danaher.

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Overweight.

Reiteration

CDTX

Cantor Fitzgerald Reiterates Overweight on Cidara Therapeutics

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Sierra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSRR#NASDAQ">BSRR</a>) with a Market Perform and lowers the price target from $24 to $23.

BSRR

Keefe, Bruyette & Woods Maintains Market Perform on Sierra, Lowers Price Target to $23

Lufax Holding shares are trading lower following a Q1 revenue miss. The company also announced a CFO transition.

Metlife's Metlife Investment Management (MIM) Announced That It Has Brought Together Its Public Fixed Income And Private Capital Offerings Into A Unified Structure Led By Jude Driscoll, Who Was Named MIM's Global Head Of Fixed Income And Private Capital

NextEra Energy Partners shares are trading higher following Q1 earnings.

Offerings

MAIA

MAIA Biotechnology Announces $1M Private Placement Of 494,096 Shares At $2.034/Share

OPCH

Option Care Health shares are trading higher after the company reported a Q1 earnings beat and raised the bottom end of its 2024 guidance range.

LOCL

Local Bounti Disclosed The Opening Of Its New Controlled Environment Agriculture Facility In Pasco, Washington On May 7

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Bank of Hawaii (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOH#NYSE">BOH</a>) with a Underperform and raises the price target from $55 to $58.

Keefe, Bruyette & Woods Maintains Underperform on Bank of Hawaii, Raises Price Target to $58

SNAL

Snail Launched Bellwright In Early Access Move To Bolster Its Standing In The Market And Reaffirm Its Commitment To Pioneering New Gaming Experiences

Kimberly-Clark Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) shares are gaining in the&nbsp;<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket session on Tuesday</a>.
The company reported first-quarter adjusted earnings per share of $2.01,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38375057/kimberly-clark-announces-first-quarter-2024-results-and-raises-2024-outlook" rel="noreferrer noopener">beating the analyst consensus of $1.63</a>.
Quarterly revenues of $5.149 billion topped the street view of $5.085 billion. Net sales were down 1%, with organic sales growth of 6% <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">versus the prior year.</a>
Gross margin was 37.1%, up 390 basis points versus the prior year, driven by organic net sales growth and gross productivity gains.
Price-led gains reflected necessary pricing actions to address higher local costs in hyperinflationary economies, mainly in&nbsp;Argentina.&nbsp;
Volume and mix were positive across&nbsp;North America, developing and emerging (D&amp;E), and developed markets (represented&nbsp;Australia,&nbsp;South Korea, and Western/Central Europe).
Adjusted operating profit increased by 14% despite an unfavorable impact of 12 percentage points from currency translation, primarily driven by hyperinflationary economies.
Year-to-date capital spending was&nbsp;$194 million&nbsp;compared to $201&nbsp;million last year.&nbsp;
The company returned&nbsp;$452 million&nbsp;to shareholders through dividends and repurchases of common stock.&nbsp;
Total debt was&nbsp;$8 billion&nbsp;as of&nbsp;March 31, 2024, consistent with&nbsp;December 31, 2023.
Outlook:&nbsp;Organic net sales&nbsp;is&nbsp;now&nbsp;expected&nbsp;to grow mid-single digits (<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">prior view: low-to mid-single-digit growth</a>).&nbsp;
The company now expects&nbsp;reported net sales&nbsp;to&nbsp;be negatively impacted&nbsp;by 400 basis points of currency translation and 120 basis points from divestitures (prior view: 300 basis points and 60 basis points, respectively).
Adjusted EPS&nbsp;is now expected&nbsp;to grow at a low-teens percentage rate on a constant-currency basis (prior view: high-single-digit growth).
Price Action: KMB shares are trading higher by 5.5% to $136.02 premarket at the last check Tuesday.
Photo via Wikimedia Commons

Equities

Kimberly-Clark +5% After Q1 Results - Here's Why

Wells Fargo analyst Andrew Nowinski upgrades Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from Equal-Weight to Overweight and raises the price target from $130 to $150.

Upgrades

DDOG

Wells Fargo Upgrades Datadog to Overweight, Raises Price Target to $150

Dividend Income Update December 2023

Embecta declares $0.15 dividend

Embecta beats top-line and bottom-line estimates; updates FY24 outlook

Embecta Corp. (EMBC) Q1 2024 Earnings Call Transcript

Embecta Corp (EMBC) reported better than expected earnings this morning for Q1 2024. Embecta Corp's earnings came in at an EPS of $0.61 per share, 33.00% higher than estimates for an EPS of $0.46 per share. The firm's earnings are down 36% since reporting $0.96 per share in the same period a year ago. Remember, earnings re

Embecta Corp Down 8.76% To $16.20 After Earnings Beat

Embecta Corporation (EMBC) has released an update to notify the public and investors about the submission of matters to a vote of security holders....

Embecta Shareholders Approve Directors and Compensation Plans

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Embecta Corporation (EMBC – Research Report), Mettler-Toledo (MTD...

Analysts Offer Insights on Healthcare Companies: Embecta Corporation (EMBC), Mettler-Toledo (MTD) and Humacyte (HUMA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on McKesson (MCK – Research Report), Embecta Corporation (EMBC – Res...

Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Embecta Corporation (EMBC) and Abbott Labs (ABT)

Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Atara Biotherapeutics (ATRA – Research Report) and Embecta Corpor...

Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)

ALLE

AMGN

ATRA

ATRI

AVGO

AVNS

GILD

HUMA

KIDS

MSFT

OSUR

TROW

VTRS

Press Releases

embecta to Participate in Investor Conferences

No embecta-made syringes impacted by FDA safety communication

embecta to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

embecta Announces FDA 510(k) Submission for Insulin Patch Pump

embecta to Report Fiscal First Quarter 2024 Financial Results

embecta to Participate in the 11th Annual BTIG MedTech Conference

Dividends

embecta Announces Quarterly Cash Dividend

Embecta Corp. Reports First Quarter Fiscal 2024 Financial Results

embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes